Protective effects of dexmedetomidine in vital organ injury: crucial roles of autophagy

Shankun Zhao1†, Weizhou Wu2†, Xuezheng Lin3†, Maolei Shen1, Zhenyu Yang3, Sicong Yu3 and Yu Luo3*

Abstract
Vital organ injury is one of the leading causes of global deaths. Accumulating studies have demonstrated that dexmedetomidine (DEX) has an outstanding protective effect on multiple organs for its anti-inflammatory and anti-apoptotic properties, while the underlying molecular mechanism is not clearly understood. Autophagy, an adaptive catabolic process, has been found to play a crucial role in the organ-protective effects of DEX. Herein, we present a first attempt to summarize all the evidence on the proposed roles of autophagy in the action of DEX protecting against vital organ injuries via a comprehensive review. We found that most of the relevant studies (17/24, 71%) demonstrated that the modulation of autophagy was inhibited under the treatment of DEX on vital organ injuries (e.g. brain, heart, kidney, and lung), but several studies suggested that the level of autophagy was dramatically increased after administration of DEX. Albeit not fully elucidated, the underlying mechanisms governing the roles of autophagy involve the anti-apoptotic properties, inhibiting inflammatory response, removing damaged mitochondria, and reducing oxidative stress, which might be facilitated by the interaction with multiple associated genes (i.e., hypoxia inducible factor-1α, p62, caspase-3, heat shock 70 kDa protein, and microRNAs) and signaling cascades (i.e., mammalian target of rapamycin, nuclear factor-kappa B, and c-Jun N-terminal kinases pathway). The authors conclude that DEX hints at a promising strategy in the management of vital organ injuries, while autophagy is crucially involved in the protective effect of DEX.

Keywords: Dexmedetomidine (DEX), Autophagy, Organ injury, Protection, Mechanism

Introduction
Vital organ injury (i.e., cerebral, myocardial, renal, and lung injury) is one of the leading causes of global deaths and seriously affects the lives of patients, resulting in great healthcare and significant economic impacts in today's society [1]. Acute organ injury occurs frequently in the perioperative period, while chronic injury is commonly caused by long-lasting stimulation and toxic insult. Ischemia–reperfusion (I/R) injury is a major cause of acute organ injury. I/R injury develops in response to interruption in the blood supply to an area of tissue, leading to persistent tissue hypoxia and severe microvascular dysfunction [2]. With the subsequent return of blood flow and oxygen supply on reperfusion, further organ injury occurs following...
oxidative stress and the action of proinflammatory chemokines and cytokines [3, 4]. I/R-mediated microcirculatory dysfunction can cause multiple organ injuries followed by the acute, subacute, and chronic phases after reperfusion, resulting in stepwise organ fibrosis and failure [5]. Chronic organ injury is often correlated with the rewiring of a complex metabolic network, imbalance of immune function, and tissue remodeling [6]. Acute, repeated, and chronic injuries without interventions commonly cause organ dysfunction. Consistently, intensive efforts have been made to develop novel therapeutic measures to effectively prevent or treat vital organ injuries.

Dexmedetomidine (DEX), a selective α2 adrenoceptor agonist, not only exerts sedative and anxiolytic effects but also exhibits sympathetic nerve suppression and antiinflammatory properties. Thus, it is broadly applied in clinical anesthesia and the intensive care unit (ICU) [7]. Basic and translational studies suggest that DEX is superior to some types of sedatives (i.e., benzodiazepines and propofol) in terms of multiple clinical outcomes, such as delirium, coma, subsequent infection, mechanical ventilation, and even 28-day mortality [8–10]. Accordingly, present sedation guidelines recommend DEX use over benzodiazepines for light-to-moderate sedation in critically ill patients [11]. In addition, DEX is not solely recommended for adult use as a short-term medication (< 24 h) for analgesia and sedation in the ICU but can also be applied for more than 24 h in ICU [12, 13]. Recently, mounting evidence has confirmed that DEX has an outstanding protective effect on multiple organs. Due to the antiinflammatory reaction and immunoregulation developed by DEX, numerous clinical trials support the notion that DEX confers multorgan protection in acute organ injury events as well as during the perioperative period [14–16]. Also, mounting experimental studies have demonstrated that DEX protects against various organ injuries using different animal models [17–19], while the mechanisms underlying this protective effect are not completely understood and are currently under investigation.

A growing body of research has revealed that autophagy might be involved in the organ-protective actions of DEX [20, 21]. Autophagy, an adaptive catabolic process, functions to maintain cellular homeostasis by engulfing cellular targets, including damaged organelles, unfolded proteins, and pathogens [22–24]. Upon diverse stress conditions, the activation and inhibition of autophagy have been speculated to play roles in the protection against organ injury. Under different interventions, altered autophagy has frequently been identified in the process of treating organ injuries [25, 26]. Similarly, autophagy abnormalities are also observed under DEX treatment of vital organ injuries, including the brain [27], heart [28], kidneys [29], liver [17], and lungs [30].

Since DEX has crucial clinical implications for treating vital organs injuries, elucidating the underlying molecular mechanisms is of pivotal importance. Autophagy may be one of the key regulators in the action of DEX protecting against organ injury. However, to the best of the authors’ knowledge, there have been no comprehensive reviews on the relationship between the DEX-mediated autophagy pathway and the treatment of vital organs injuries. Therefore, it is timely to summarize and discuss the current evidence on this issue.
Pharmacokinetic properties of DEX

4-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole (DEX) is the dextro-enantiomer of medetomidine, with molecular formula C\textsubscript{13}H\textsubscript{16}N\textsubscript{2} (molecular mass 236.7 g/mol; octanol/water partition coefficient 2.89) \cite{31, 32}. DEX is currently approved for intravenous use, while the loading doses and infusion rates are based on a milligram per kilogram total body weight. DEX shows high protein binding (94% is bound to albumin and α1-glycoprotein) with an extensive volume of distribution (1.31–2.46 L/kg) and simply crosses the blood–brain barrier \cite{32}. The elimination half-life of DEX in the adult health population and ICU patients is 2.1–3.1 h and 2.2–3.7 h, respectively \cite{32, 33}, while the metabolic clearance in adult patients and ICU patients is 36–42 l/h and 31.8–57 l/h, respectively \cite{33, 34}. In children, the elimination half-life of DEX is approximate 2 h \cite{35}.

The pharmacodynamics of DEX includes sedative and hypnotic effects, analgesic effects, cardiovascular effects, respiratory effects, etc. The sedative and hypnotic effects developed by DEX may be associated with activation of central presynaptic and postsynaptic alpha\textsubscript{2} adrenoceptor in the locus coeruleus, regulation of endogenous sleep-promoting pathways, and an impact on the γ-aminobutyric acid system \cite{32}. Significant and rousable sedation effects induced by DEX are recorded at plasma concentrations between 0.2 and 0.3 ng/mL. The analgesic effects of DEX are thought to be mediated through alteration of perception and reduction of anxiety. DEX has a biphasic hemodynamic effect on the cardiovascular system, showing that low plasma concentrations induce hypotension whereas higher concentrations lead to pulmonary and systemic hypertension \cite{36}. As reported, the hypertensive effects of DEX overcome the hypotensive effects at concentrations between 1.9 and 3.2 ng/mL \cite{36}. Minimal respiratory depression is observed at therapeutic plasma concentrations up to 2.4 ng/mL, showing a preservation of ventilatory response to CO\textsubscript{2} \cite{37}. The ventilatory frequency can elevate with dose escalation of DEX, which compensates for slightly decreased tidal volumes \cite{32}. With target concentrations between 0.2 and 0.6 ng/mL of DEX, no relevant pharmacokinetic interactions were identified in DEX when combining with propofol, isoflurane, midazolam, or alfentanil \cite{32}.

Current knowledge

α2-Receptors are frequently detected in various vital organs, including the central nervous system, kidneys, lungs, and liver \cite{32}. Since DEX is a highly selective α2 adrenoceptor agonist, it may mediate a broad spectrum of pharmacodynamic actions on these organs. In numerous animal studies \cite{18, 38, 39}, DEX appears to alleviate the inflammation responses and the I/R injury of multiple organs, i.e., the brain, liver, and intestines. More importantly, although α2 adrenoceptor is not found in the myocardium, a large body of previous studies suggest that DEX plays a protective role on myocardial I/R injury \cite{40, 41}. DEX-mediated modulation of autophagy is considered to play the adrenergic receptor agonist’s protective role in multiple organ injuries. Based on the above evidence, DEX exerts an encouraging protective effect on multiple organs. Mechanistically, recent experimental research has suggested that autophagy might be involved in this action. In this review, we thus outline the molecular and biological functions of autophagy in DEX-mediated organ-protective effects.
Literature search
A comprehensive review of the literature was undertaken using six databases (MEDLINE, EMBASE, Google Scholar, Cochrane Library, Web of Science, and PsychINFO) to identify relevant studies. The searching strategy in MEDLINE using MeSH and keywords was: ((((((((((("Autophagy"[Mesh]) OR (Autophagy, Cellular)) OR (Cellular Autophagy)) OR (Autophagocytosis)) OR (Reticulophagy)) OR (ER-Phagy)) OR (ER Phagy)) OR (Nucleophagy)) OR (Ribophagy)) OR (Lipophagy)) AND ((((("Dexmedetomidine"[Mesh]) OR (MPV-1440)) OR (MPV 1440)) OR (MPV1440)) OR (Precedex)) OR (Dexmedetomidine Hydrochloride)) OR (Hydrochloride, Dexmedetomidine)). The reference list was also reviewed to detect additional studies. A data collection table was applied to extract the key data from the relevant studies, including the first author’s name, publication year, geographical distribution, cell/animal model, types of organ injury, DEX administration, autophagy status, associated genes or pathways, and the main findings of the included studies. Finally, 24 studies [21, 27–30, 41–59] were included. Among these, 14, 4, 3, and 3 eligible studies reported cerebral injury, myocardial injury, kidney injury, and lung injury, respectively.

Organ-protective properties of DEX and the roles of autophagy
Cerebral injury
Fourteen publications reported autophagy involving the action of the protective effect of DEX in brain injury. The experimental models among these eligible studies included rat, mouse, and neurocyte (i.e., astrocytes, PC12, and neuroblastoma cells). The types of central nervous injury included cerebral ischemia/reperfusion injury, traumatic brain injury, neurological injury, cognitive impairment, hippocampus injury, oxygen–glucose deprivation–reoxygenation injury, and neonatal hypoxic ischemia. The route for DEX administration in an animal model included intraperitoneal injection and intravenous injection via the femoral vein or the caudal vein. The dose of DEX in a rat model ranged from 3 to 50 μg/kg, but 20–25 μg/kg in a mouse model. DEX in a cell model was administrated through cell supernatants, while the dose of DEX was 1 μM. Most of the included studies (12/14, 86%) reported the status of autophagy was inhibition in the protective effect of DEX in cerebral injury. Multiple genes and signaling pathways have been found to be involved in autophagy-mediated neuroprotection by DEX.

The characteristics and the main findings of the 14 relevant studies reporting cerebral injury are summarized in Table 1. Figure 1 shows the main mechanisms of autophagy in the cerebra-protective effects of DEX.

mTOR signaling pathway
The phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is one of the most important signaling pathways with a critical biological function in various diseases [60, 61], including neurological disorders [62]. As reported, numerous drugs exert their neuroprotective effect via the PI3K/Akt/mTOR signaling pathway [63]. mTOR is considered to serve as a central player in the regulation of autophagy because it can inhibit autophagy in the process of growth factors and abundant nutrients [64]. Shen et al. [42] demonstrated that DEX alleviated the degree of
| Study/ref.          | Experimental model | Types of injury                | DEX administration | Status of autophagy | Associated genes or pathways                                                                 | Main findings                                                                                                                                 |
|--------------------|--------------------|--------------------------------|-------------------|--------------------|---------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|
| Luo et al. 2017 [27] | Mouse              | Ischemic cerebral injury       | Intraperitoneally, 25 μg/kg | Inhibited         | Upregulating HIF-1α                                                                          | Postconditioning with DEX at beginning of reperfusion protects mouse brain from ischemia–reperfusion injury via inhibition of neuronal autophagy by upregulating of Bcl-1, p62, and HIF-1α and downregulating of LC3 and Beclin 1 |
| Shen et al. 2017 [42] | Rat                | Traumatic brain injury         | Injected via the left femoral vein, 15 μg/kg | Inhibited         | Activation of the PI3K/Akt/mTOR pathway                                                     | DEX alleviates the degree of traumatic brain injury via inhibition of neurotic autophagy by activating PI3K/AKT/mTOR signaling pathway        |
| Shan et al. 2018 [43] | Pregnant rat       | Neurological injury            | Intraperitoneally, 20 μg/kg | Inhibited         | Upregulating Bcl2, downregulating Drp1 and Bax                                             | DEX improved the abnormal morphology of hippocampal CA1 regions of rat-pup brains and inhibited sevoflurane-induced activation of autophagy     |
| Yi et al. 2018 [44]  | Rat                | Cognitive impairment           | Intraperitoneally, 4 μg/kg  | Inhibited         | Downregulating of LC3-I, LC3-II, and Beclin-1                                              | DEX improved the cognitive dysfunction in aged rats under sevoflurane anesthesia by decreasing autophagy of hippocampal neurons              |
| Lu et al. 2019 [45]  | Rat                | Cerebral ischemia-reperfusion injury | Intraperitoneally, 50 μg/kg   | Inhibited         | Downregulation of Bax and Caspase-3, upregulation in Bcl-2 and HSP70                       | DEX exerts neuroprotective effect by inducing mild hypothermia, slowing down heart rate, attenuating apoptosis of neurocytes, and repressing autophagy |
| Study/ref. | Experimental model | Types of injury | DEX administration | Status of autophagy | Associated genes or pathways | Main findings |
|------------|-------------------|----------------|-------------------|-------------------|-----------------------------|--------------|
| Zhu et al. 2019 [46] | Rat | Cerebral ischemia/reperfusion injury | Left femoral vein, 3 μg/kg | Inhibited | Inhibiting the activation of JNK signaling pathway | The effect of DEX might be related to the inhibition of JNK pathway activation, and to affect the expressions of inflammatory factors and autophagy-related proteins |
| Tang et al. 2019 [47] | SH-SYSY cells | Ischemia/reperfusion cerebral injury | Treated with 1 μM DEX for 18 h reoxygenation | Inhibited | Downregulating LC3 and Beclin 1, upregulating BCL-2, p62, and TOM20 | DEX increased the cell survival meanwhile reduced the production of autophagic vesicles, as well as regulated some related proteins |
| Li et al. 2020 [50] | Rat | Traumatic brain injury | Intraperitoneally, 20 μg/kg | Inhibited | Inactivation of the circLrp1b/miR-27a-3p/Dram2 signaling pathway | DEX inhibits inflammatory response and autophagy in a traumatic brain injury rat model by acting on the circLrp1b/miR-27a-3p/Dram2 pathway |
| Yu et al. 2020 [21] | Rat | Hippocampus injury | Intraperitoneally, 25 μg/kg | Activated mitophagy | Increased expression levels of FOXO3α, BINF3, LC3-II/LC3-I, and P62 | DEX attenuated hippocampus injury and improved cognitive function by activating SIRT3-mediated mitophagy and inhibiting activation of the NLRP3 inflammasome |
| Zhu et al. 2020 [48] | Mouse and astrocytes | Cerebral ischemia | 1 μM, via medium | Activated astrocytes autophagy | Upregulating TSC2 and 4EBP1, downregulating mTOR | DEX increases the viability and inhibits apoptosis of astrocytes exposed to oxygen–glucose deprivation, which might be related to the activation of autophagy by regulating TSC2/mTOR pathway |
| Study/ref. | Experimental model | Types of injury | DEX administration | Status of autophagy | Associated genes or pathways | Main findings |
|-----------|--------------------|----------------|-------------------|-------------------|-----------------------------|---------------|
| Hu et al. 2020 [49] | PC12 Cells | OGD/R injury | 1 µg/mL, via medium | Inhibited | Decreasing the levels of STIM1 and Orai1 proteins | DEX attenuates cell apoptosis following OGD/R by inhibiting autophagy in PC12 cells, which may be correlated to the repression of Ca$^{2+}$-STIM1/Orai signaling |
| Zhu et al. 2021 [52] | Rat | Cerebral ischemia/reperfusion | Caudal vein, 3 µg/kg/h | Inhibited | Inhibiting the expression of miR-199a | DEX inhibited autophagy and decreased nerve cell injury by decreasing the level of miR-199a |
| Xue et al. 2021 [51] | Rat | Neonatal hypoxic ischemia | Intraperitoneally, 25 µg/kg | Inhibited | Down-regulating LC3B-II and Beclin 1 | Protective effects of DEX were evidenced by the inhibition of excessive autophagy of neurons and microglia, reducing the decline of long-term neuronal density and axon demyelination |
| Feng et al. 2021 [53] | Mouse | Traumatic brain injury | Intraperitoneally, 20 µg/kg | Inhibited | Decreasing the levels of ROS and MDA, and increasing the expression of Nrf2 and HO-1 | DEX improves neurological outcomes and reduces neuronal death by protecting against neural autophagy and neuroinflammation by regulating the ROS/Nrf2 pathway |

OGD/R: oxygen–glucose deprivation–reoxygenation
traumatic brain injury via inhibition of neuronic autophagy by activating the PI3K/AKT/mTOR signaling pathway. In line with this finding, some investigators also found that the inhibition of neuronic autophagy was one of the therapeutic targets for traumatic brain injury treatment [65]. Also, the protective effects of DEX are speculated to be against the process of autophagy and apoptosis. Zhu et al. [48] reported that DEX increased the viability and inhibits apoptosis of astrocytes exposed to oxygen–glucose deprivation, which might be related to the activation of autophagy by regulating the tuberous

Fig. 1 Main mechanisms of autophagy in the cerebra-protective effects of DEX. DEX is one the α2AR agonists. Under administration of DEX in treating cerebral injury, the autophagy level was regulated by multiple associated genes and a series of downstream signaling, resulting in reduction of inflammatory, apoptosis, and damaged mitochondria. DEX dexmedetomidine, HIF-1α hypoxia inducible factor-1α, LC3 light chain 3 B, Drp1 dynamin-related protein 1, HSP70 heat shock 70 kDa protein, TOM20 translocase of outer mitochondrial membrane 20, Dram2 DNA damage regulated autophagy modulator 2, FOXO3a forkhead-box-protein 3a, TSC2 tuberous sclerosis complex 2, STIM1 stromal interaction molecule 1, ROS reactive oxygen species, MDA malondialdehyde, Nrf2 nuclear factor erythroid 2-related factor 2
sclerosis complex 2 (TSC2)/mTOR pathway. The authors indicated that DEX treatment could upregulate the expression of TSC2 and subsequently reduce the phosphorylation of mTOR. In contrast to Shen et al.'s study, Zhu et al. found that the protective effect played by DEX might be associated with augmented autophagy of astrocytes. Consistent with Zhu et al.'s findings, Yu et al. [21] demonstrated that DEX attenuated hippocampus injury by activating SIRT3-mediated mitophagy. Of note, Zhu et al. and Yu, et al.'s studies are the only two included studies (2/14, 14%) reporting that the status of autophagy is activation when treating with DEX for cerebral injury. Commonly, autophagy is activated in cerebral injury [66], while DEX may inhibit the autophagy level and thus contribute to the neuroprotection in cerebral damage [53]. With the same cell line of astrocytes as used in Zhu et al.'s study [48], Qin et al. [67] suggested that the inhibition of autophagy might exert the protective effect on astrocytes after ischemic astrocyte injury. This could be partially explained by the finding that autophagy may play different roles in different cerebral injury stages, i.e., ischemia and reperfusion [48]. The exact roles of autophagy at different timepoints after cerebral injury deserve further investigation.

**MicroRNAs (miRNAs)**

miRNAs are a major class of conserved short noncoding RNAs with crucial biological functions in the regulation of a third of the whole genome at the posttranslational level [68]. miRNAs exert their roles by increasing messenger RNA degradation or by blocking messenger RNA translation [69]. Numerous studies have suggested that there is a close association between miRNAs and autophagy in various diseases, including cerebral injury [70]. Also, miRNAs-mediated autophagy and the signaling cascades might play critical roles in the effect of DEX in protecting cerebral injury. Li et al. [50] showed that DEX could improve the neurological outcome in a traumatic brain injury rat model by inhibiting autophagy and regulating the circLrp1b/miR-27a-3p/Dram2 pathway. They found that the protective effect of DEX after cerebral injury might be attributable to the downregulation of circLrp1b and the inhibition of injury-induced autophagy, while these effects were dramatically abolished by miR-27a-3p suppression. Zhu et al. reported that the autophagy level in the cerebral cortex increased in an animal model of cerebral ischemia/reperfusion injury, while inhibited autophagy was observed after treating with DEX. During this action, Zhu et al. further found that DEX significantly inhibited the expression of miR-199a and thus improved neurocyte injury. The above evidence indicated that inhibition of autophagy might be involved in the DEX-induced neuroprotective effect in cerebral injury.

**Autophagy-associated proteins (Beclin-1, Bcl-2, LC3-I, and LC3-II)**

The therapeutic implications of DEX in brain injury may also be strongly associated with the altered expression of autophagy-associated proteins such as Beclin-1, Bcl-2, LC3-I, and LC3-II. Beclin-1 is involved in the initiation and maturation steps of autophagy, constituting the primary component of the autophagy mechanism [71]. Bcl-2, one of the key interacting proteins of Beclin-1 and the antiapoptotic family members, can suppress autophagy initiation by inhibiting the cascade of autophagy formation [72]. Both LC3-I and LC3-II are biomarkers for autophagy. LC3B-II/I indicates the generation of autophagosomes. Shan et al. [43] found that DEX improved the abnormal morphology
of hippocampal CA1 regions of rat-pup brains by inhibiting sevoflurane-induced activation of autophagy via upregulating Bcl-2. Lu et al. demonstrated that DEX exerted a neuroprotective effect by repressing autophagy in a cerebral ischemia/reperfusion injury rat model, which was partially caused by the upregulation of Bcl-2 expression. Xue et al. [51] showed that the protective effects of DEX were evidenced by the inhibition of excessive autophagy of neurons and microglia through downregulating LC3B-II and Beclin1. In line with Xue et al's findings, Yi et al. [44] found that the protective functioning developed by DEX might be via decreasing autophagy of hippocampal neurons, which presented with the reduction of LC3-I, LC3-II, and Beclin-1 expression. In contrast, though Yu et al. [21] detected that DEX attenuated hippocampus injury, they observed that the status of mitophagy was activated, characterized by enhancing LC3-II/LC3-I expression.

**Other associated genes**

In addition to the above factors, the roles of autophagy in the neuroprotective effects mediated by DEX might also be caused by some other associated proteins and signaling pathways, e.g., HIF-1α, p62, Drp1, Caspase-3, HSP70, TOM20, Dram2, FOXO3α, BINP3, TSC2, 4EBP1, STIM1, Orai1, ROS, MDA, Nrf2, HO-1, and JNK signaling [21, 27, 43, 45–50, 53]. Among these genes, a positive correlation has been found between autophagy and Drp1, Caspase-3, Dram2, FOXO3α, BINP3, TSC2, 4EBP1, STIM1, Orai1, ROS, MDA, and JNK signaling pathway. In contrast, autophagy has a negative relationship with the expression of HIF-1α, p62, HSP70, TOM20, Nrf2, and HO-1. All these genes and signaling cascades might be linked to biogenesis and biological functions of autophagy in the neuroprotective action of DEX.

**Myocardial injury**

DEX has also been reported to elicit cardioprotective effects via various molecule mechanisms. Autophagy regulation is considered to be one of the proposed mechanisms, which is believed to constitute a crucial process in the self-preservation of the heart. As reported, autophagy machinery involves immunity modulation through transmitting microbes to lysosomes for degradation and facilitating the release of cytokines for microbe digestion [73]. To date, four experimental studies have confirmed the essential roles of autophagy in DEX-mediated cardioprotection [28, 41, 54, 55] (Table 2). According to Yu et al’s study, DEX could attenuate septic myocardial injury by increasing autophagic flux via activating α7nAChR and the Akt/GSK-3β cascades, resulting in a reduction of the myocardium apoptosis and inflammatory response. In line with this finding, Xiao et al. also found that autophagy upregulation was associated with the action that DEX protected human cardiomyocytes against I/R injury. They further observed that α2-adrenergic receptor/AMPK signaling cascades greatly contributed to the activation of autophagy during the protective process developed by DEX.

Conversely, although two other studies [41, 54] have also reported that DEX treatment significantly attenuated myocardium injury, the researchers found that the autophagy status was inhibited in this process. Zhang et al. [54] demonstrated that DEX alleviated myocardial ischemia/reperfusion injury by dramatically decreasing overautophagy and reducing cardiomyocyte apoptosis, oxidative stress, and inflammatory reactions via upregulating the SIRT1/mTOR axis. DEX postconditioning could result in a decrease
### Table 2  Characteristics and main findings of relevant studies reporting on myocardial, kidney, and lung injury

| Study/ref.   | Experimental model | Types of injury                          | DEX administration | Status of autophagy | Associated genes or pathways | Main findings                                                                                                                                                                                                 |
|-------------|--------------------|------------------------------------------|--------------------|---------------------|-----------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|             |                    |                                          |                    |                     |                             | Myocardial injury                                                                                                                  |
| Yu et al. 2019 [28] | Rat              | Septic myocardial dysfunction          | Injection, 50 μg/kg | Promoted           | Upregulating 7nAChR and the PI3K/Akt pathway | DEX attenuates the myocardium injury by mediating autophagic flux; DEX decreases the myocardium apoptosis and inflammatory response mediated by increased autophagy by activating α7nAChR and the PI3K/Akt pathway |
| Zhang et al. 2020 [54] | Rat              | Myocardial ischemia/reperfusion injury | Intravenous injection, 10 μg/kg | Inhibited         | Upregulating the SIRT1/mTOR pathway | DEX reduces cardiomyocyte apoptosis, oxidative stress, and inflammatory reactions via upregulating the SIRT1/mTOR axis and decreasing overautophagy in myocardial ischemia/reperfusion injury rats |
| Xiao et al. 2021 [55] | Cardiomyocytes | Myocardial ischemia/reperfusion injury | 5 μM DEX was added to the culture media | Upregulated      | Upregulating AMP-activated protein kinase (AMPK) and phospho AMPK | DEX protected human cardiomyocytes from apoptosis and was associated with autophagy; the protection of DEX for H/R injury was AMPK dependent and α2-adrenergic receptor dependent |
| Li et al. 2021 [41] | Rat              | Myocardial ischemia/reperfusion injury | Injected through the jugular vein catheter, 10 μg/kg | Inhibited        | Upregulating Beclin1 and activating the PI3K/Akt pathway | DEX upregulates the phosphorylation of Beclin 1 at S295 site by activating the PI3K/Akt pathway and reduces the interactions of Atg14L–Beclin1–Vps34 complex, thus inhibiting autophagy and protecting against myocardial ischemia/reperfusion injury |

Kidney injury

Li et al. 2019 [23] | Rat  | Urine infection | Intravenous injection, 10 mg/kg | Inhibited | Upregulating Beclin1 and activating the PI3K/Akt pathway | DEX protects against renal injury by enhancing autophagy and inhibiting proteinuria and fibrosis. |

Lung injury

Chen et al. 2020 [24] | Rat | Lung injury | Intravenous injection, 10 mg/kg | Inhibited | Upregulating Beclin1 and activating the PI3K/Akt pathway | DEX protects against lung injury by enhancing autophagy and inhibiting inflammation and fibrosis. |
| Study/ref. | Experimental model | Types of injury | DEX administration | Status of autophagy | Associated genes or pathways | Main findings |
|-----------|-------------------|----------------|--------------------|-------------------|-----------------------------|--------------|
|           |                   |                |                    |                   |                             |              |
|           |                   |                |                    |                   |                             |              |
| Kidney injury                        |                |                |                    |                   |                             |              |
| Lempainen et al. 2014 [29] | Rat       | Cerebral kidney ischemia–reperfusion injury | Intravenous injection, 10 μg/kg | Enhanced          | Upregulating renal p38 MAPK   | DEX preconditioning ameliorates kidney ischemia–reperfusion injury and inflammatory response via the enhancement of autophagy and the regulation of the p38-CD44 pathway |
| Yang et al. 2020 [56] | Rat       | Lipopolysaccharide-induced acute kidney injury | Intraperitoneally, 30 μg/kg | Enhanced          | Upregulating the expression of p-AMPK and downregulating p-mTOR   | DEX ameliorates inflammatory response by reducing NLRP3 inflammasome and inflammatory cytokines by enhancing autophagy via the AMPK/mTOR pathway |
| Zhao et al. 2020 [57] | Rat       | Lipopolysaccharide-induced acute kidney injury | Intraperitoneally, 30 μg/kg | Enhanced          | Inhibition of the PI3K/AKT/mTOR pathway   | DEX protects against LPS-induced acute kidney injury by enhancing autophagy, thus removing the damaged mitochondria and reducing oxidative stress and apoptosis through the α2-AR and inhibition of the PI3K/AKT/mTOR pathway |
| Lung injury                        |                |                |                    |                   |                             |              |
| Zhang et al. 2017 [30] | Rat       | Lung ischemia/reperfusion injury | Administered intravenously, 10 μg/kg | Inhibited        | Upregulating the level of HIF-1α, downregulating BNIP3, BNIP3 L, and LC3II | Preconditioning with DEX provided protection against lung injury in a dose-dependent manner by inhibiting autophagy, which might be associated with the upregulation of HIF-1α and downregulation of BNIP3 and BNIP3 L |
| Study/ref. | Experimental model | Types of injury | DEX administration | Status of autophagy | Associated genes or pathways | Main findings |
|-----------|---------------------|-----------------|-------------------|---------------------|-----------------------------|--------------|
| Ding et al. 2018 [58] | Mouse | Lipopolysaccharide-induced acute lung injury | Intravenously injected, 50 μg/kg | Inhibited | Inhibition of the TLR4-NF-κB pathway | DEX protects against acute lung injury via reducing the inflammatory response and inhibiting autophagy-related proteins and signaling pathway |
| Li et al. 2021 [59] | Rat | Toxic shock-induced lung injury | Intraperitoneally, 50 μg/kg | Inhibited | Decreasing the expression of pERK1/2 protein | DEX protects against lung injury by inhibiting autophagy and inflammation |

*IPSC cell human induced pluripotent stem cell*
of LC3II and Beclin-1 and an elevation of p62 protein level, thus inhibiting autophagy. Li et al. [41] reported that DEX upregulated the phosphorylation of Beclin1 by activating the PI3K/Akt pathway and reduced the interactions of Atg14L–Beclin 1–Vps34 complex, thus inhibiting autophagy and protecting against myocardial ischemia/reperfusion injury. As shown in Table 2, DEX administration in both Zhang et al. and Li et al.'s study was based on intravenous injection, and the dose was the same at 10 μg/kg.

The mechanisms of autophagy in the myocardial-protective effects of DEX are illustrated in Fig. 2.

Kidney injury
Acute kidney injury, a disease with high morbidity and mortality, is closely associated with multiple organ dysfunction. Kidney I/R injury and sepsis are the two main causes for the development of acute kidney injury. Autophagy has been shown to elicit some protective effects in the pathological processes of renal tubular injury [74]. A previous study [29] suggested that DEX preconditioning ameliorated kidney I/R injury and inflammatory response via the enhancement of autophagy and upregulation of the renal p38-CD44 pathway. The authors found that autophagy was markedly downregulated by kidney I/R injury, while intravenous treatment with 10 μg/kg DEX effectively prevented the impairment of the autophagic response, thus maintaining the degradation and recycling of multiple cellular components [29]. Consistent with this finding, two subsequent studies also observed that the renoprotective effects of DEX were mediated by the enhancement of autophagy after kidney injury. In a lipopolysaccharide-induced acute kidney injury rat model, Yang et al. demonstrated that DEX ameliorated the inflammatory response by reducing the NLRP3 inflammasome and inflammatory cytokines by enhancing autophagy via the AMPK/mTOR pathway. With the same acute kidney injury model, Zhao et al. found that DEX could protect against kidney injury by enhancing autophagy, thus removing damaged mitochondria and reducing oxidative stress and apoptosis through α2-AR and inhibition of the PI3K/AKT/mTOR pathway. Both animal models in Yang et al. and Zhao et al.'s studies were treated with DEX by intravenous injection with a dose of 30 μg/kg. The characteristics of the above relevant studies
reporting kidney injury are summarized in Table 2. The mechanisms of autophagy in the kidney-protective effects of DEX are illustrated in Fig. 3 (upper).

**Lung injury**

Acute lung injury, one of the serious forms of diffuse lung disease, has high morbidity and mortality and imposes a substantial health burden globally [75]. The common causes of acute lung injury include serious infection, burns, trauma, and shock. Fluid conservative strategy and lung-protective ventilation are the two certain supportive treatments to treat acute lung injury effectively. Recently, DEX has been suggested to exert protective effects on pulmonary functions in acute lung injury and ventilator-induced lung injury [76]. Mechanistically, the lung-protective effects developed by DEX might be correlated to the autophagy-associated signaling pathways. To date, three studies [30, 58, 59] have reported the roles of autophagy in the action of DEX attenuating lung injury. All these studies indicated that the autophagic response was inhibited when treated with DEX in an animal model of lung injury. Zhang et al. [30] reported that preconditioning with DEX protected against lung injury in a dose-dependent manner by inhibiting autophagy, which might be associated with the upregulation of HIF-1α and downregulation of BNIP3 and BNIP3 L in a lung ischemia/reperfusion injury rat model. Ding et al. [58] showed that DEX protected against lipopolysaccharide-induced acute lung injury via reducing the inflammatory response and inhibiting autophagy-related proteins and the TLR4-NF-κB signaling pathway. Based on a toxic shock-induced lung injury rat model, Li et al. [59] found that DEX remarkably protected against lung injury by inhibiting autophagy and inflammation by decreasing the expression of pERK1/2 protein. The administration of DEX was the same in the above studies, viz. 50 μg/kg DEX intravenously. The characteristics of the relevant studies reporting lung injury are listed in Table 2, while the underlying mechanisms of autophagy in the protective effects of DEX are shown in Fig. 3 (lower).
Limitations and perspectives
To the best of the authors’ knowledge, this is the first comprehensive review to summarize all the evidence of the crucial roles of autophagy in the action of DEX protecting against vital organ injuries. First, all the included studies listed in Tables 1 and 2 were either in vivo or in vitro experiments. The exact roles of autophagy in the human body under DEX treatment in organ injury have not been fully understood yet, which deserves further investigation. Second, the level of autophagy flux in the process of the DEX-mediated protective effect on organ injury is still controversial among different studies. Most of the included studies (17/24, 71%) demonstrated that the modulation of autophagy was inhibited during this process, but the remaining studies indicated that the autophagy level was promoted. This phenomenon is particularly observed in myocardial injury, with half of the included studies reporting inhibition and half reporting enhancement of the autophagy level. This inconsistency regarding the autophagy level might be due to the various timepoints monitored in different studies. Besides, autophagy may play a dual role in the protective effect against organ injury, which needs further investigation.

Conclusions
This review highlights the crucial roles of autophagy in the protective effect of DEX on multiple vital organs, including cerebral, myocardial, kidney, and lung injuries. The vast majority of the included studies have shown that the autophagy level is suppressed under treatment with DEX in organ injuries, but several studies suggested that the level of autophagy was dramatically increased after administration of DEX. Albeit not fully elucidated, the underlying mechanisms governing the roles of autophagy involve the antiapoptotic properties, inhibiting inflammatory response, removing damaged mitochondria, and reducing oxidative stress, which may be facilitated by the interaction with multiple associated proteins and signaling cascades. With the progress of extensive in-depth studies, DEX-mediated autophagy will be fully understood to guide better clinical applications for organ protection.

Abbreviations
DEX: Dexmedetomidine; HIF-1α: Hypoxia inducible factor-1α; LC3: Light chain 3 B; Drp1: Dynamin-related protein 1; HSP70: Heat shock 70 kDa protein; TOM20: Translocase of outer mitochondrial membrane 20; Dram2: DNA damage regulated autophagy modulator 2; FOXO3a: Forkhead-box-protein 3α; TSC2: Tuberous sclerosis complex 2; STIM1: Stromal interaction molecule 1; ROS: Reactive oxygen species; MDA: Malondialdehyde; Nrf2: Nuclear factor erythroid 2-related factor 2; 7nAChR: α7 nicotinic acetylcholine receptor; SIRT1: Sirtuin 1; AMPK: Adenosine monophosphate-activated protein kinase; VPS34: Vacuolar protein sorting 34; MAPK: Mitogen-activated protein kinase; BNIP3: B cell lymphoma 2 interacting protein 3; TLR4: Toll-like receptor 4; ERK: Extracellular signal regulated kinases.

Acknowledgements
None.

Author contributions
S.K.Z., W.Z.W., and X.Z.L. contributed to the conception and design of the study. S.C.Y. performed the systematic search. X.Z.L. extracted the data. S.K.Z. and Y.L. wrote the manuscript. W.Z.W., Y.L., M.L.S., and Z.Y.Y. supervised the manuscript. All the authors read and approved the final manuscript.

Funding
This work was supported by grants from the Zhejiang Medical and Health Science and Technology Program (no. 2022RC297), Natural Science Foundation of Zhejiang Province (no. LQ22H04009), Science and Technology Planning Project of Taizhou City, Zhejiang Province (no. 20yw40 & no. 21yw38), and High-level Hospital Construction Research Project of Maoming People’s Hospital.

Availability of data and materials
Not applicable.
Declarations

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Urology, Taizhou Central Hospital (Taizhou University Hospital), Taizhou 318000, Zhejiang, China. 2Department of Urology, Maoming People’s Hospital, Maoming 525000, Guangdong, China. 3Department of Anesthesia Surgery, Taizhou Central Hospital (Taizhou University Hospital), Taizhou 318000, China.

Received: 28 February 2022    Accepted: 12 April 2022

Published online: 04 May 2022

References

1. D’Alessio FR, Kurzhagen JT, Rabb H. Reparative T lymphocytes in organ injury. J Clin Invest. 2019;129(7):2608–18.

2. Zhao H, Kågls S, Alam A, Eguchi S, Ma D. The role of extracellular adenosine triphosphate in ischemic organ injury. Crit Care. 2016;20(5):1000–12.

3. Land WG. The role of postischemic reperfusion injury and other nonantigen-dependent inflammatory pathways in transplantation. Transplantation. 2005;79(5):S05–14.

4. Cai Y, Xu H, Yan J, Zhang L, Lu Y. Molecular targets and mechanism of action of dexmedetomidine in treatment of ischemia/reperfusion injury. Mol Med Rep. 2014;9(5):1542–50.

5. Han JY, Li Q, Ma ZZ, Fan JY. Effects and mechanisms of compound Chinese medicine and major ingredients on microcirculatory dysfunction and organ injury induced by ischemia/reperfusion. Pharmacol Ther. 2017;177:146–73.

6. Ritchie RH, Abel ED. Basic mechanisms of diabetic heart disease. Circ Res. 2020;126(11):1501–25.

7. Demiri M, Antunes T, Fletcher D, Martinez V. Perioperative adverse events attributed to alpha2-adrenoceptor agonists in patients not at risk of cardiovascular events: systematic review and meta-analysis. Br J Anaesth. 2019;123(6):795–807.

8. Pandharipande PP, Pun BT, Herr DL, Maze M, Girard TD, Miller RR, Shintani AK, Thompson JL, Jackson JC, Deppen SA, et al. Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial. JAMA. 2007;298(22):2644–53.

9. Riker RR, Shehabi Y, Bokesch PM, Ceraso D, Lindsell C, Martinelli EP, Mo E, Nunnally ME, Rochwerg B, et al. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. Crit Care Med. 2018;46(9):e825–37.

10. Shehabi Y, Ruettmann U, Adamson H, Innes R, Ickeringill M. Dexmedetomidine infusion for more than 24 hours in critically ill patients: a randomized controlled trial. JAMA. 2009;301(5):489–99.

11. Pandharipande PP, Sanders RD, Girard TD, McGrane S, Thompson JL, Shintani AK, Herr DL, Maze M, Ely EW. Effect of dexmedetomidine versus lorazepam on outcome in patients with sepsis: an a priori-designed analysis of the MENDS randomized controlled trial. Crit Care. 2010;14(2):R38.

12. Devlin JW, Skrobik Y, Gelinca M, Needham DM, Slooter A, Pandharipande PP, Watson PL, Wehner PW, Nunally ME, Rochwerg B, et al. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. Crit Care Med. 2018;46(9):e825–37.

13. Shehabi Y, Ruettmann U, Adamson H, Innes R, Ickeringill M. Dexmedetomidine infusion for more than 24 hours in critically ill patients: sedative and cardiovascular effects. Intensive Care Med. 2004;30(12):2188–96.

14. Gertler R, Brown HC, Mitchell DH, Silvisus EN. Dexmedetomidine: a novel sedative-analgesic agent. Proc (Bayl Univ Med Cent). 2001;14(1):13–21.

15. Biccard BM, Goga S, de Beurs J. Dexmedetomidine and cardiac protection for non-cardiac surgery: a meta-analysis of randomised controlled trials. Anaesthesia. 2008;63(1):4–14.

16. Gong Z, Ma L, Zhong YL, Li J, LV Jie YB. Myocardial protective effects of dexmedetomidine in patients undergoing cardiac surgery: a meta-analysis and systematic review. Exp Ther Med. 2017;13(5):2355–61.

17. Liu J, Shi K, Hong J, Gong F, Mo S, Chen M, Zheng Y, Jiang L, Xu L, Xu Y, et al. Dexmedetomidine protects against acute kidney injury in patients with septic shock. Ann Palliat Med. 2020;9(2):224–30.

18. Yu Q, Zou L, Yuan X, Fang F, Xu F. Dexmedetomidine protects against septic liver injury by enhancing autophagy through activation of the AMPK/SIRT1 signaling pathway. Front Pharmacol. 2021;12:658677.

19. Wang N, Nie H, Wang S, Liu W, Tian K. Dexmedetomidine exerts cerebral protective effects against cerebral ischemic injury by promoting the polarization of M2 microglia via the Nrf2/HO-1/NLRP3 pathway. Inflamm Res. 2021. https://doi.org/10.1007/s00011-021-01515-5.

20. Hu G, Shi Z, Shao W, Xu B. MicroRNA-214–5p involves in the protection effect of dexmedetomidine against neurologic injury in Alzheimer’s disease via targeting the suppressor of zest 12. Brain Res Bull. 2021. https://doi.org/10.1016/j.brainresbull.2021.10.016.

21. Unchiti K, Leurcharusme P, Samerchua A, Pipanmekaporn T, Chattipakorn N, Chattipakorn SC. The potential role of dexmedetomidine on outcome in patients with sepsis: an a priori-designed analysis of the MENDS randomized controlled trial. JAMA. 2007;298(22):2644–53.
23. Su H, Yang F, Fu R, Li X, French R, Mose E, Fu X, Trinh B, Kumar A, Liu J, et al. Cancer cells escape autophagy inhibition via NFR2-induced macropinocytosis. Cancer Cell. 2021;39(5):678–93.

24. Yla-Anttila P. Autophagy receptors as viral targets. Cell Mol Biol Lett. 2021;26(1):29.

25. Liu L, Cao Q, Gao W, Li BY, Zeng C, Xia Z, Zhao B. Melatonin ameliorates cerebral ischemia-reperfusion injury in diabetic rats by enhancing autophagy via the SIRT1-BMAL1 pathway. FASEB J. 2021;35(12):e22040.

26. Qin GW, Lu P, Peng L, Jiang W. Ginsenoside Rb1 inhibits cardiomyocyte autophagy via PI3K/Akt/mTOR signaling pathway and reduces myocardial ischemia/reperfusion injury. Am J Chin Med. 2021. https://doi.org/10.1142/S0192415X21500907.

27. Luo C, Ouyang MW, Fang YY, Li SJ, Zhou Q, Fan J, Qin ZS, Tao T. Dexmedetomidine protects mouse brain from ischemia-reperfusion injury via inhibiting neuronal autophagy through up-regulating HIF-1alpha. Front Cell Neurosci. 2017;11:197.

28. Yu T, Liu Q, Gao M, Yang P, Zhang M, Song F, Zhang X, Liu Y. Dexmedetomidine prevents septic myocardial dysfunction in rats via activation of alpha7nAChR and PI3K/Akt-mediated autophagy. Biomed Pharmacother. 2019;120:109231.

29. Lempiainen J, Finckenberg P, Mervaala EE, Storvik M, Kaivola J, Lindstedt K, Levijoki J, Mervaala EM. Dexmedetomidine preconditioning ameliorates kidney ischemia-reperfusion injury. Pharmacol Res Perspect. 2014;2(3):e45.

30. Zhang W, Zhang J. Dexmedetomidine preconditioning protects against lung injury induced by ischemia-reperfusion through inhibition of autophagy. Exp Ther Med. 2017;14(2):973–80.

31. Castillo RL, Ibáñaceh M, Cortínez I, Carrasco-Pozo C, Farias JS, Carrasco RA, Vargas-Errazuriz P, Ramos D, Benavente R, Torres DH, et al. Dexmedetomidine improves cardiovascular and ventilatory outcomes in critically ill patients: basic and clinical approaches. Front Pharmacol. 2019;10:1641.

32. Weerinink S, Struyfs J, Hannivoot LN, Barends C, Absalom AR, Colin P. Clinical pharmacokinetics and pharmacodynamics of dexmedetomidine. Clin Pharmacokinet. 2017;56(8):893–915.

33. Zhu Y, Zheng Y, He P, He Z, Wang X. Effects of mild hypoalbuninaemia on the pharmacokinetics and pharmacodynamics of dexmedetomidine in patients after major abdominal or thoracic surgery. J Clin Anesth. 2015;27(8):632–7.

34. Khan ZP, Munday IT, Jones RM, Thornton C, Mant TG, Amin D. Effects of dexmedetomidine on isoflurane requirements in healthy volunteers: 1. Pharmacodynamic and pharmacokinetic interactions. Br J Anaesth. 1999;83(3):372–80.

35. Mason KP, Lerman J. Review article: dexmedetomidine in children: current knowledge and future applications. Anesth Analg. 2011;113(5):1129–42.

36. Ebert TJ, Hall JE, Barney JA, Ulrich TD, Colind MD. The effects of increasing plasma concentrations of dexmedetomidine in humans. Anesthesiology. 2000;93(2):382–94.

37. Hsu YW, Cortínez IJ, Robertson KM, Keifer JC, Sum-Ping ST, Moretti EW, Young CC, Wright DR, MacLeod DB, Somma J. Dexmedetomidine pharmacokinetics: part I: crossover comparison of the respiratory effects of dexmedetomidine and remifentanil in healthy volunteers. Anesthesiology. 2004;101(5):1066–76.

38. Wu Y, Qiu G, Zhang H, Zhu L, Cheng G, Wang Y, Li Y, Wu W. Dexmedetomidine alleviates hepatic ischaemia-reperfusion injury via the PI3K/AKT/NF-2/NLRP3 pathway. J Cell Mol Med. 2021;25(21):9983–94.

39. VanderBroek AR, Englesie JB, Kastner S, Kopp V, Verhaar N, Hopster K. Protective effects of dexmedetomidine on small intestinal ischaemia-reperfusion injury in horses. Equine Vet J. 2021;53(S3):569–78.

40. Chen Y, Cao S, Chen H, Yin C, Xu Y, Yang Z. Dexmedetomidine preconditioning reduces myocardial ischemia-reperfusion injury in rats by inhibiting the PERK pathway. ARQ Bras Cardiol. 2021.

41. Li Y, Qi M, Xing F, Li H, Cheng G, Xing N, Zhang W. The protective mechanism of dexmedetomidine in regulating Atg14L-Beclin1-Vps34 complex against myocardial ischemia-reperfusion injury. J Cardiovasc Transl Res. 2021. https://doi.org/10.1007/s12265-021-10125-9.

42. Shen M, Wang S, Wen X, Han XR, Wang YJ, Zhou XM, Zhang MH, Wu DM, Lu J, Zheng YL. Dexmedetomidine exerts neuroprotective effect via the activation of the PI3K/Akt/mTOR signaling pathway in rats with traumatic brain injury. Biomed Pharmacother. 2017;95:885–93.

43. Shan Y, Sun S, Yang F, Zhang N, Liu H. Dexmedetomidine protects the developing rat brain against the neurotoxicity wrought by sevoflurane: role of autophagy and Orp1-Bax signaling. Drug Des Devel Therap. 2018;12:3617–24.

44. Yi C, Fu Z, Luo X. Dexmedetomidine on autophagy of hippocampal neurons in aged rats under sevoflurane anesthesia. Exp Ther Med. 2018;16(2):837–41.

45. Lu J, Liu J, Zhu JL, Shen Y, Zhang ZW, Zhu CL. Hypothymic properties of dexmedetomidine provide neuroprotection in rats following cerebral ischemia-reperfusion injury. Exp Ther Med. 2019;18(1):817–25.

46. Zhu Y, Li S, Liu J, Wen Q, Yu J, Yu L, Xie K. Role of JNK signaling pathway in dexmedetomidine post-conditioning-induced reduction of the inflammatory response and autophagy effect of focal cerebral ischemia reperfusion injury in rats. Inflammation. 2019;42(6):2181–91.

47. Tang Y, Jia C, He J, Zhao Y, Chen H, Wang S. The application and analytical pathway of dexmedetomidine in ischemia/reperfusion injury. J Anal Methods Chem. 2019;2019:7158142.

48. Zhu C, Zhou Q, Luo C, Chen Y. Dexmedetomidine protects against oxygen-glucose deprivation-induced injury through inducing astrocytes autophagy via TSC2/mTOR pathway. Neuromol Med. 2020;12(21):21687–705.

49. Xue H, Wu Z, Xu Y, Gao Q, Zhang Y, Li C, Zhao P. Dexmedetomidine post-conditioning ameliorates long-term neurological outcomes after neonatal hypoxic ischemia: the role of autophagy. Life Sci. 2021;1270:118980.

50. Zhu Y, Zhao H, Zhang W, Ma X, Liu Y. Dexmedetomidine attenuates neuronal injury induced by cerebral ischaemia-reperfusion by regulating miR199a. Mol Med Rep. 2021. https://doi.org/10.3892/mmr.2021.12213.
53. Feng X, Ma W, Zhu J, Jiao W, Wang Y. Dexmedetomidine alleviates early brain injury following traumatic brain injury by inhibiting autophagy and neuroinflammation through the ROS/Nrf2 signaling pathway. Mol Med Rep. 2021. https://doi.org/10.3892/mmr.2021.12300.

54. Zhang X, Li Y, Wang Y, Zhuang Y, Ren Y, Yang K, Ma W, Zhong M. Dexmedetomidine postconditioning suppresses myocardial ischemia/reperfusion injury by activating the SIRT1/mTOR axis. 2020. BioSci Rep. https://doi.org/10.1042/BSR20190430.

55. Xiao Y, Li J, Qiu L, Jiang C, Huang Y, Liu J, Sun Q, Hong H, Ye L. Dexmedetomidine protects human cardiomyocytes against ischemia-reperfusion injury through alpha2-adrenergic receptor/AMPK-dependent autophagy. Front Pharmacol. 2021;12: 615424.

56. Yang T, Feng X, Zhao Y, Zhang H, Cui H, Wei M, Yang H, Fan H. Dexmedetomidine enhances autophagy via alpha2-AR/AMPK/mTOR pathway to inhibit the activation of NLRP3 inflammasome and subsequently alleviates lipopolysaccharide-induced acute kidney injury. Front Pharmacol. 2020;11:790.

57. Zhao Y, Feng X, Li B, Sha J, Wang C, Yang T, Cui H, Fan H. Dexmedetomidine protects against lipopolysaccharide-induced acute kidney injury by enhancing autophagy through inhibition of the PI3K/Akt/mTOR pathway. Front Pharmacol. 2020;11:128.

58. Ding D, Xu S, Zhang H, Zhao W, Zhang X, Jiang Y, Wang P, Dai Z, Zhang J. 3-Methyladenine and dexmedetomidine reverse lipopolysaccharide-induced acute lung injury through the inhibition of inflammation and autophagy. Exp Ther Med. 2018;15(4):3516–22.

59. Li ZB, Li GC, Qin J. Dexmedetomidine attenuates lung injury in toxic shock rats by inhibiting inflammation and autophagy. Arch Med Res. 2021;52(3):277–83.

60. Akbarzadeh M, Mihanfar A, Akbarzadeh S, Yousefi B, Majidinia M. Crosstalk between miRNA and PI3K/Akt/mTOR signaling pathway in cancer. Life Sci. 2021;285: 119984.

61. Wang Z, Huang Y, Zhang J. Molecularly targeting the PI3K-Akt-mTOR pathway can sensitize cancer cells to radiotherapy and chemotherapy. Cell Mol Biol Lett. 2014;19(2):233–42.

62. Zhang D, Yuan Y, Zhu J, Zhu D, Li C, Cui W, Wang L, Ma S, Duan S, Liu B. Insulin-like growth factor 1 promotes neurofunctional recovery after spinal cord injury through inhibition of autophagy via the PI3K/Akt/mTOR signaling pathway. Exp Ther Med. 2021;22(5):1265.

63. Chen A, Xiong LJ, Tong Y, Mao M. Neuroprotective effect of brain-derived neurotrophic factor mediated by autophagy through the PI3K/Akt/mTOR pathway. Mol Med Rep. 2013;8(4):1011–6.

64. Li X, Li J, Zhang Y, Zhou Y. Di-n-butyl phthalate induced hypospadias relates to autophagy in genital tubercle via the PI3K/Akt/mTOR pathway. J Occup Health. 2017;59(1):8–16.

65. Luo CL, Li BX, Li QQ, Chen XP, Sun YX, Bao HJ, Dai DK, Shen YW, Xu HF, Ni H, et al. Autophagy is involved in traumatic brain injury-induced cell death and contributes to functional outcome deficits in mice. Neuroscience. 2011;184:54–63.

66. Rami A, Kogel D. Apoptosis meets autophagy-like cell death in the ischemic penumbra: two sides of the same coin? Autophagy. 2008;4(4):422–6.

67. Qin AP, Liu CF, Qin YY, Hong LZ, Xu M, Yang L, Liu J, Qin ZH, Zhang HL. Autophagy was activated in injured astrocytes and mildly decreased cell survival following glucose and oxygen deprivation and focal cerebral ischemia. Autophagy. 2010;6(6):738–53.

68. Letafati A, Najafi S, Mottahedi M, Karimzadeh M, Shahini A, Garousi A, Abbassi-Kolli M, Sadri NJ, Tamehri ZS, Hamblin MR, et al. MicroRNA let-7 and viral infections: focus on mechanisms of action. Cell Mol Biol Lett. 2022;27(1):14.

69. Saliminejad K, Khorram KH, Soleymani FS, Ghaffari SH. An overview of microRNAs: biology, functions, therapeutics, and analysis methods. J Cell Physiol. 2019;234(5):5451–65.

70. Xu Q, Guehui M, Li D, Bai F, Fang J, Zhang G, Xing Y, Zhou J, Guo Y, Kan Y. IncRNA C2dat2 facilitates autophagy and apoptosis via the miR-30d-5p/DDIT4/mTOR axis in cerebral ischemia-reperfusion injury. Aging (Albany NY). 2021;13(8):11315–35.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.